ADC Therapeutics SA - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADCT New York 2836 www.adctherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ADC Therapeutics SA

ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma - Dec 4th, 2025 5:40 am
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Dec 3rd, 2025 5:30 am
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial - Dec 2nd, 2025 2:05 pm
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - Dec 1st, 2025 2:05 pm
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Dec 1st, 2025 7:40 am
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know - Nov 18th, 2025 10:00 am
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... - Nov 10th, 2025 2:01 pm
ADC Therapeutics (ADCT) Earnings Call Transcript - Nov 10th, 2025 7:17 am
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates - Nov 10th, 2025 6:40 am
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update - Nov 10th, 2025 5:30 am
Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y - Nov 7th, 2025 10:51 am
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates - Nov 6th, 2025 3:45 pm
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates - Nov 3rd, 2025 4:05 pm
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 - Nov 3rd, 2025 5:15 am
Breast Cancer Antibody Drug Conjugates Market Research 2025-2030: $7 Billion Market Led by Daiichi Sankyo and AstraZeneca, with Rising Competition from Roche, Pfizer/Seagen, ADC Therapeutics - Nov 3rd, 2025 3:54 am
ADC Therapeutics to Present at November Investor Conferences - Oct 27th, 2025 5:15 am
ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted - Oct 26th, 2025 4:16 am
H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement - Oct 24th, 2025 6:07 am
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain - Oct 13th, 2025 11:06 am
ADC Therapeutics Announces $60 Million Private Placement - Oct 13th, 2025 5:30 am